Technique of vessel-skeletonized parenchyma-sparing hepatectomy for the oncological treatment of bilobar colorectal liver metastases.
Colorectal cancer
Hepatectomy
Liver metastasis
Parenchyma-sparing
Vessel skeletonization
Journal
Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
21
07
2021
accepted:
30
10
2021
pubmed:
29
11
2021
medline:
23
3
2022
entrez:
28
11
2021
Statut:
ppublish
Résumé
To aid in the oncological management of multiple bilobar colorectal liver metastases (CRLMs), we describe a new surgical procedure, VEssel-Skeletonized PArenchyma-sparing Hepatectomy (VESPAH). Of 152 patients with CRLMs treated with hepatectomy, 33 patients had multiple bilobar liver metastases (≥8 liver metastases); their surgical procedures and clinical outcomes were retrospectively summarized and compared between those who underwent VESPAH and those who underwent major hepatectomy (Major Hx). Of the 33 patients, 20 patients were resected by VESPAH (the VESPAH group) and 13 patients by major hepatectomy (Major Hx group). The median number of CRLMs was 13 (range, 8-53) in the VESPAH group and 10 (range, 8-41) in the Major Hx group (P=0.511). No operative mortality nor severe morbidity was observed in either group. The VESPAH group showed earlier recovery of remnant liver function after surgery than the Major Hx group; the incidence of grade B/C post hepatectomy liver failure was 5% in the VESPAH group and 38% in the Major Hx group, P=0.048). Intrahepatic tumor recurrence was confirmed in 14 (70%) and 7 (54%) patients in the VESPAH and Major Hx groups, respectively (P=0.416). There was no significant difference in median overall survival (OS) after hepatectomy between the two groups; the median OS was 47 months in the VESPAH group and 33 months in the Major Hx group (P=0.481). The VESPAH group showed the higher induction rate of adjuvant chemotherapy within 2 months after surgery (P=0.002) and total number of repeat hepatectomy for intrahepatic recurrence (P=0.060) than the Major Hx group. VESPAH enables us to clear surgical navigation by hepatic vessel skeletonization and may enhance patient tolerability of not only adjuvant chemotherapy but also repeat hepatectomies during the patients' lifetimes.
Sections du résumé
BACKGROUND
BACKGROUND
To aid in the oncological management of multiple bilobar colorectal liver metastases (CRLMs), we describe a new surgical procedure, VEssel-Skeletonized PArenchyma-sparing Hepatectomy (VESPAH).
STUDY DESIGN
METHODS
Of 152 patients with CRLMs treated with hepatectomy, 33 patients had multiple bilobar liver metastases (≥8 liver metastases); their surgical procedures and clinical outcomes were retrospectively summarized and compared between those who underwent VESPAH and those who underwent major hepatectomy (Major Hx).
RESULTS
RESULTS
Of the 33 patients, 20 patients were resected by VESPAH (the VESPAH group) and 13 patients by major hepatectomy (Major Hx group). The median number of CRLMs was 13 (range, 8-53) in the VESPAH group and 10 (range, 8-41) in the Major Hx group (P=0.511). No operative mortality nor severe morbidity was observed in either group. The VESPAH group showed earlier recovery of remnant liver function after surgery than the Major Hx group; the incidence of grade B/C post hepatectomy liver failure was 5% in the VESPAH group and 38% in the Major Hx group, P=0.048). Intrahepatic tumor recurrence was confirmed in 14 (70%) and 7 (54%) patients in the VESPAH and Major Hx groups, respectively (P=0.416). There was no significant difference in median overall survival (OS) after hepatectomy between the two groups; the median OS was 47 months in the VESPAH group and 33 months in the Major Hx group (P=0.481). The VESPAH group showed the higher induction rate of adjuvant chemotherapy within 2 months after surgery (P=0.002) and total number of repeat hepatectomy for intrahepatic recurrence (P=0.060) than the Major Hx group.
CONCLUSIONS
CONCLUSIONS
VESPAH enables us to clear surgical navigation by hepatic vessel skeletonization and may enhance patient tolerability of not only adjuvant chemotherapy but also repeat hepatectomies during the patients' lifetimes.
Identifiants
pubmed: 34839388
doi: 10.1007/s00423-021-02373-9
pii: 10.1007/s00423-021-02373-9
pmc: PMC8933371
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
685-697Subventions
Organisme : the japan society for the promotion of science
ID : 19K09217
Informations de copyright
© 2021. The Author(s).
Références
Adam R (2003) Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 14(Suppl 2):ii13-6. https://doi.org/10.1093/annonc/mdg731
doi: 10.1093/annonc/mdg731
pubmed: 12810452
Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247(1):125–135. https://doi.org/10.1097/SLA.0b013e31815aa2c2
doi: 10.1097/SLA.0b013e31815aa2c2
pubmed: 18156932
Adam R, Aloia T, Levi F, Wicherts DA, de Haas RJ, Paule B et al (2007) Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25(29):4593–4602. https://doi.org/10.1200/JCO.2007.10.8126
doi: 10.1200/JCO.2007.10.8126
pubmed: 17925554
Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11(1):38–47. https://doi.org/10.1016/S1470-2045(09)70330-4
doi: 10.1016/S1470-2045(09)70330-4
pubmed: 19942479
Broering DC, Hillert C, Krupski G, Fischer L, Mueller L, Achilles EG et al (2002) Portal vein embolization vs. portal vein ligation for induction of hypertrophy of the future liver remnant. J Gastrointest Surg 6(6):905–13. https://doi.org/10.1016/s1091-255x(02)00122-1 (discussion 13)
doi: 10.1016/s1091-255x(02)00122-1
pubmed: 12504230
Azoulay D, Castaing D, Smail A, Adam R, Cailliez V, Laurent A et al (2000) Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg 231(4):480–486. https://doi.org/10.1097/00000658-200004000-00005
doi: 10.1097/00000658-200004000-00005
pubmed: 10749607
pmcid: 1421022
Vauthey JN, Chaoui A, Do KA, Bilimoria MM, Fenstermacher MJ, Charnsangavej C et al (2000) Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 127(5):512–519. https://doi.org/10.1067/msy.2000.105294
doi: 10.1067/msy.2000.105294
pubmed: 10819059
Shoup M, Gonen M, D’Angelica M, Jarnagin WR, DeMatteo RP, Schwartz LH et al (2003) Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 7(3):325–330. https://doi.org/10.1016/s1091-255x(02)00370-0
doi: 10.1016/s1091-255x(02)00370-0
pubmed: 12654556
Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA et al (2012) Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 255(3):405–414. https://doi.org/10.1097/SLA.0b013e31824856f5
doi: 10.1097/SLA.0b013e31824856f5
pubmed: 22330038
Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H (2000) Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 232(6):777–785. https://doi.org/10.1097/00000658-200012000-00006
doi: 10.1097/00000658-200012000-00006
pubmed: 11088072
pmcid: 1421270
Schadde E, Ardiles V, Robles-Campos R, Malago M, Machado M, Hernandez-Alejandro R et al (2014) Early survival and safety of ALPPS: first report of the International ALPPS Registry. Ann Surg 260(5):829–36. https://doi.org/10.1097/SLA.0000000000000947 (discussion 36-8)
doi: 10.1097/SLA.0000000000000947
pubmed: 25379854
Chua TC, Liauw W, Chu F, Morris DL (2013) Summary outcomes of two-stage resection for advanced colorectal liver metastases. J Surg Oncol 107(2):211–216. https://doi.org/10.1002/jso.23170
doi: 10.1002/jso.23170
pubmed: 22648977
Linecker M, Stavrou GA, Oldhafer KJ, Jenner RM, Seifert B, Lurje G et al (2016) The ALPPS risk score: avoiding futile use of ALPPS. Ann Surg 264(5):763–771. https://doi.org/10.1097/SLA.0000000000001914
doi: 10.1097/SLA.0000000000001914
pubmed: 27455156
Tanaka K, Shimada H, Matsumoto C, Matsuo K, Takeda K, Nagano Y et al (2008) Impact of the degree of liver resection on survival for patients with multiple liver metastases from colorectal cancer. World J Surg 32(9):2057–2069. https://doi.org/10.1007/s00268-008-9610-0
doi: 10.1007/s00268-008-9610-0
pubmed: 18454272
Sarpel U, Bonavia AS, Grucela A, Roayaie S, Schwartz ME, Labow DM (2009) Does anatomic versus nonanatomic resection affect recurrence and survival in patients undergoing surgery for colorectal liver metastasis? Ann Surg Oncol 16(2):379–384. https://doi.org/10.1245/s10434-008-0218-2
doi: 10.1245/s10434-008-0218-2
pubmed: 19020941
Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M et al (2001) Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma. Am J Surg 181(2):153–159. https://doi.org/10.1016/s0002-9610(00)00560-2
doi: 10.1016/s0002-9610(00)00560-2
pubmed: 11425058
Hosokawa I, Allard MA, Mirza DF, Kaiser G, Barroso E, Lapointe R et al (2017) Outcomes of parenchyma-preserving hepatectomy and right hepatectomy for solitary small colorectal liver metastasis: a LiverMetSurvey study. Surgery 162(2):223–232. https://doi.org/10.1016/j.surg.2017.02.012
doi: 10.1016/j.surg.2017.02.012
pubmed: 28434557
Beppu T, Sakamoto Y, Hasegawa K, Honda G, Tanaka K, Kotera Y et al (2012) A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 19(1):72–84. https://doi.org/10.1007/s00534-011-0460-z
doi: 10.1007/s00534-011-0460-z
pubmed: 22020927
Margonis GA, Sasaki K, Gholami S, Kim Y, Andreatos N, Rezaee N et al (2018) Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases. Br J Surg 105(9):1210–1220. https://doi.org/10.1002/bjs.10838
doi: 10.1002/bjs.10838
pubmed: 29691844
pmcid: 7988484
Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L et al (2011) Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery 149(5):680–688. https://doi.org/10.1016/j.surg.2010.12.002
doi: 10.1016/j.surg.2010.12.002
pubmed: 21316725
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213
doi: 10.1097/01.sla.0000133083.54934.ae
pubmed: 15273542
pmcid: 1360123
de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R (2008) R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg 248(4):626–637. https://doi.org/10.1097/SLA.0b013e31818a07f1
doi: 10.1097/SLA.0b013e31818a07f1
pubmed: 18936576
Strasberg SM (2005) Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 12(5):351–355. https://doi.org/10.1007/s00534-005-0999-7
doi: 10.1007/s00534-005-0999-7
pubmed: 16258801
Vigano L, Procopio F, Cimino MM, Donadon M, Gatti A, Costa G et al (2016) Is tumor detachment from vascular structures equivalent to R0 resection in surgery for colorectal liver metastases? An observational cohort. Ann Surg Oncol. 23(4):1352–1360. https://doi.org/10.1245/s10434-015-5009-y
doi: 10.1245/s10434-015-5009-y
pubmed: 26714946
Vigano L, Costa G, Cimino MM, Procopio F, Donadon M, Del Fabbro D et al (2018) R1 resection for colorectal liver metastases: a survey questioning surgeons about its incidence, clinical impact, and management. J Gastrointest Surg 22(10):1752–1763. https://doi.org/10.1007/s11605-018-3820-z
doi: 10.1007/s11605-018-3820-z
pubmed: 29948554
Torzilli G, Garancini M, Donadon M, Cimino M, Procopio F, Montorsi M (2010) Intraoperative ultrasonographic detection of communicating veins between adjacent hepatic veins during hepatectomy for tumours at the hepatocaval confluence. Br J Surg 97(12):1867–1873. https://doi.org/10.1002/bjs.7230
doi: 10.1002/bjs.7230
pubmed: 20799289
Krausch M, Raffel A, Anlauf M, Schott M, Lehwald N, Krieg A et al (2014) “Cherry picking”, a multiple non-anatomic liver resection technique, as a promising option for diffuse liver metastases in patients with neuroendocrine tumours. World J Surg 38(2):392–401. https://doi.org/10.1007/s00268-013-2267-3
doi: 10.1007/s00268-013-2267-3
pubmed: 24101025
Yamamoto M, Ariizumi SI (2018) Glissonean pedicle approach in liver surgery. Ann Gastroenterol Surg 2(2):124–128. https://doi.org/10.1002/ags3.12062
doi: 10.1002/ags3.12062
pubmed: 29863152
pmcid: 5881351
Makuuchi M, Hasegawa H, Yamazaki S (1985) Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet 161(4):346–350
pubmed: 2996162
Alvarez FA, Sanchez Claria R, Oggero S, de Santibanes E (2016) Parenchymal-sparing liver surgery in patients with colorectal carcinoma liver metastases. World J Gastrointest Surg 8(6):407–423. https://doi.org/10.4240/wjgs.v8.i6.407
doi: 10.4240/wjgs.v8.i6.407
pubmed: 27358673
pmcid: 4919708
Imai K, Benitez CC, Allard MA, Vibert E, Cunha AS, Cherqui D et al (2015) Failure to achieve a 2-stage hepatectomy for colorectal liver metastases: how to prevent it? Ann Surg 262(5):772–8. https://doi.org/10.1097/SLA.0000000000001449 (discussion 8-9)
doi: 10.1097/SLA.0000000000001449
pubmed: 26583665
Olthof PB, Huiskens J, Wicherts DA, Huespe PE, Ardiles V, Robles-Campos R et al (2017) Survival after associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced colorectal liver metastases: a case-matched comparison with palliative systemic therapy. Surgery 161(4):909–919. https://doi.org/10.1016/j.surg.2016.10.032
doi: 10.1016/j.surg.2016.10.032
pubmed: 28038862
Petrowsky H, Linecker M, Raptis DA, Kuemmerli C, Fritsch R, Kirimker OE et al (2020) First long-term oncologic results of the ALPPS procedure in a large cohort of patients with colorectal liver metastases. Ann Surg 272(5):793–800. https://doi.org/10.1097/SLA.0000000000004330
doi: 10.1097/SLA.0000000000004330
pubmed: 32833765
Harun N, Nikfarjam M, Muralidharan V, Christophi C (2007) Liver regeneration stimulates tumor metastases. J Surg Res 138(2):284–290. https://doi.org/10.1016/j.jss.2006.06.024
doi: 10.1016/j.jss.2006.06.024
pubmed: 17254608
Matsumoto K, Miyake Y, Umeda Y, Matsushita H, Matsuda H, Takaki A et al (2013) Serial changes of serum growth factor levels and liver regeneration after partial hepatectomy in healthy humans. Int J Mol Sci 14(10):20877–20889. https://doi.org/10.3390/ijms141020877
doi: 10.3390/ijms141020877
pubmed: 24141186
pmcid: 3821648
Yoon SS, Kim SH, Gonen M, Heffernan NM, Detwiller KY, Jarnagin WR et al (2006) Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol 13(3):353–362. https://doi.org/10.1245/ASO.2006.03.060
doi: 10.1245/ASO.2006.03.060
pubmed: 16474912
Torzilli G, Vigano L, Cimino M, Imai K, Vibert E, Donadon M et al (2018) Is enhanced one-stage hepatectomy a safe and feasible alternative to the two-stage hepatectomy in the setting of multiple bilobar colorectal liver metastases? A comparative analysis between two pioneering centers. Dig Surg 35(4):323–332. https://doi.org/10.1159/000486210
doi: 10.1159/000486210
pubmed: 29439275
Torzilli G, Serenari M, Vigano L, Cimino M, Benini C, Massani M et al (2019) Outcomes of enhanced one-stage ultrasound-guided hepatectomy for bilobar colorectal liver metastases compared to those of ALPPS: a multicenter case-match analysis. HPB (Oxford) 21(10):1411–1418. https://doi.org/10.1016/j.hpb.2019.04.001
doi: 10.1016/j.hpb.2019.04.001
Tanaka K, Nakagawa K, Yabushita Y, Hiroshima Y, Matsuo K, Ota M et al (2014) Reversal of attachment to or invasion of major intrahepatic vessels by colorectal liver metastases according to prehepatectomy chemotherapy regimen. Surgery 155(5):936–944. https://doi.org/10.1016/j.surg.2013.12.030
doi: 10.1016/j.surg.2013.12.030
pubmed: 24656858
Sugioka A, Kato Y, Tanahashi Y (2017) Systematic extrahepatic Glissonean pedicle isolation for anatomical liver resection based on Laennec’s capsule: proposal of a novel comprehensive surgical anatomy of the liver. J Hepatobiliary Pancreat Sci 24(1):17–23. https://doi.org/10.1002/jhbp.410
doi: 10.1002/jhbp.410
pubmed: 28156078
pmcid: 5299460
Kiguchi G, Sugioka A, Kato Y, Uyama I (2019) Use of the inter-Laennec approach for laparoscopic anatomical right posterior sectionectomy in semi-prone position. Surg Oncol 29:140–141. https://doi.org/10.1016/j.suronc.2019.05.001
doi: 10.1016/j.suronc.2019.05.001
pubmed: 31196479